Skin CancerNCT06489301
Mechanisms for Laser-Induced Rejuvenation
A study testing Fractionated Laser Resurfacing in people with Skin Cancer, run by Wright State University at 1 site in United States.
Trial summary
It has shown that laser wounding of geriatric skin protects it against skin cancer. The purpose of this study is to determine the origin of cells called fibroblasts which are present after treatment with Fractionated Laser Resurfacing (FLR). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Skin Cancer
- What is being tested?
- Fractionated Laser Resurfacing
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Jul 2025to Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult males and females 18 and older
- Able to comprehend procedures and risks
- Planning to undergo abdominoplasty surgery
- Minimum amount of skin to be removed is 50 x 20cm
Who cannot join
- Medical history of not well-controlled diabetes. This is defined as a subject who needs high doses of insulin, recent history of hospitalization for diabetes-related complications, or poor wound health as evidenced by diabetic ulcers. Subjects who have been deemed healthy enough for abdominoplasty surgery would tend to suggest that their diabetes should not be an issue. However, if the subjects have diabetic complications as outlined above, they could affect the wound healing which is the object of this protocol so they would be excluded.
- Pregnant or nursing
- History of pathologically abnormal wound healing such as keloidal scars
- Existing tattoos on the abdomen that are so extensive that they could interfere with the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Pharmacology Translational Unit
Fairborn, Ohio, 45324
Pharmacology Translational Unit, 937-245-7500, pturesearch@wrightstatephysicians.org
About this study
It has shown that laser wounding of geriatric skin protects it against skin cancer. The purpose of this study is to determine the origin of cells called fibroblasts which are present after treatment with Fractionated Laser Resurfacing (FLR). These cells restore a youth-like ultraviolet B (UVB) response, but where they come from is currently unknown. The study recruits subjects who are scheduled to undergo abdominoplasties to investigate the origin of those cells stimulated by laser treatment.
- Conditions
- Skin Cancer
- Being tested
- Fractionated Laser Resurfacing
- Medical subject headings
- Skin Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fractionated Laser ResurfacingDevice
A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
| Study group | Role | What they receive |
|---|---|---|
| Fractionated Laser Resurfacing | Experimental | At 14 days prior to scheduled surgery a 5x5cm square on the left abdomen within the region of skin to be excised and treated with fractionated laser resurfacing. Then at 7 days prior to scheduled surgery a 5 cm diameter circle on the right abdomen within the region of skin to be excised, at least 10 cm away from the square, is treated with fractionated laser resurfacing. Receives: Device: Fractionated Laser Resurfacing |
What is being measured
The primary outcome is the main question the study is designed to answer.
To test if the new fibroblasts that develop in response to fractionated laser resurfacing (FLR) wounding are derived from blood-derived monocytes.
Identify cells in the skin that have been wounded by FLR at 2 weeks and 1 week previously, for cells that co-express markers for both fibroblasts and monocytes by using single cell RNA-sequencing
Measured: 2 weeks prior to skin removal and 1 week prior to skin removal
To test if possible cells transitioning from monocytes to fibroblasts are found in the top part of the dermis (papillary dermis).
Using tissue RNA-seq, PI will define if co-expressing cells are in the papillary dermis.
Measured: 2 weeks prior to skin removal and 1 week prior to skin removal
Secondary outcomes (3)
To define the number and types of cells populating the skin following fractionated laser resurfacing (FLR) wounding
Define the number and types of cells following FLR wounding at 2 weeks and 1 week prior to skin removal by using single-cell RNA-seq.
Measured: 2 weeks prior to skin removal and 1 week prior to skin removal
To define the locations of the number of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Define the locations of the number cell following FLR wounding at 2 weeks and 1 week prior to skin removal by using tissue RNA-seq.
Measured: 2 weeks prior to skin removal and 1 week prior to skin removal
To define the locations of the types of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Define the locations of the different cell types following FLR wounding at 2 weeks and 1 week prior to skin removal by using tissue RNA-seq.
Measured: 2 weeks prior to skin removal and 1 week prior to skin removal
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jul 2024
- Study start16 Jul 2025
- Primary completionDec 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All subjects will receive fractionated laser resurfacing.
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Wright State University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jeffrey Travers, MD, PhD, Principal investigator, Wright State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06489301
- Sponsor's protocol ID
- 2023-312
- Status last verified
- May 2026
- First submitted
- 21 May 2024
- Last updated
- 22 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mechanisms for Laser-Induced Rejuvenation
- ClinicalTrials.gov ID
- NCT06489301
- Acronym / sponsor ID
- 2023-312
- Conditions
- Skin Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Wright State UniversityUniversity, hospital or other
- Study start
- 16 Jul 2025 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 5 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It has shown that laser wounding of geriatric skin protects it against skin cancer. The purpose of this study is to determine the origin of cells called fibroblasts which are present after treatment with Fractionated Laser Resurfacing (FLR). These cells restore a youth-like ultraviolet B (UVB) response, but where they come from is currently unknown. The study recruits subjects who are scheduled to undergo abdominoplasties to investigate the origin of those cells stimulated by laser treatment.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All subjects will receive fractionated laser resurfacing.
| Arm | Type | Receives |
|---|---|---|
| Fractionated Laser Resurfacing | Experimental | Device: Fractionated Laser ResurfacingAt 14 days prior to scheduled surgery a 5x5cm square on the left abdomen within the region of skin to be excised and treated with fractionated laser resurfacing. Then at 7 days prior to scheduled surgery a 5 cm diameter circle on the right abdomen within the region of skin to be excised, at least 10 cm away from the square, is treated with fractionated laser resurfacing. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult males and females 18 and older
- Able to comprehend procedures and risks
- Planning to undergo abdominoplasty surgery
- Minimum amount of skin to be removed is 50 x 20cm
Key exclusion criteria (4 listed)
- Medical history of not well-controlled diabetes. This is defined as a subject who needs high doses of insulin, recent history of hospitalization for diabetes-related complications, or poor wound health as evidenced by diabetic ulcers. Subjects who have been deemed healthy enough for abdominoplasty surgery would tend to suggest that their diabetes should not be an issue. However, if the subjects have diabetic complications as outlined above, they could affect the wound healing which is the object of this protocol so they would be excluded.
- Pregnant or nursing
- History of pathologically abnormal wound healing such as keloidal scars
- Existing tattoos on the abdomen that are so extensive that they could interfere with the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fractionated Laser ResurfacingA rejuvenating laser that makes tiny holes in the very superficial part of the skin. | Device | Fractionated Laser Resurfacing |
Primary outcome
To test if the new fibroblasts that develop in response to fractionated laser resurfacing (FLR) wounding are derived from blood-derived monocytes.
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
Identify cells in the skin that have been wounded by FLR at 2 weeks and 1 week previously, for cells that co-express markers for both fibroblasts and monocytes by using single cell RNA-sequencing
To test if possible cells transitioning from monocytes to fibroblasts are found in the top part of the dermis (papillary dermis).
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
Using tissue RNA-seq, PI will define if co-expressing cells are in the papillary dermis.
3 secondary outcomes
To define the number and types of cells populating the skin following fractionated laser resurfacing (FLR) wounding
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
To define the locations of the number of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
To define the locations of the types of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Time frame: 2 weeks prior to skin removal and 1 week prior to skin removal
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
Related trials for Skin Cancer
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Not yet recruitingPhase 2
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Breast Neoplasms, Advanced Breast Cancer
RecruitingPhase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Active, not recruitingPhase 2
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Breast Cancer Stage IV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jeffrey Travers, MD, PhD principal investigator
Wright State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fractionated Laser Resurfacing in people with Skin Cancer, run by Wright State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Manager, Clinical Research Operations (937-245-7500, pturesearch@wrightstatephysicians.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To test if the new fibroblasts that develop in response to fractionated laser resurfacing (FLR) wounding are derived from blood-derived monocytes. (time frame: 2 weeks prior to skin removal and 1 week prior to skin removal). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.